These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 1444883)

  • 1. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease.
    Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME
    Arch Neurol; 1992 Nov; 49(11):1161-7. PubMed ID: 1444883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease.
    Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME
    Ann Neurol; 1990 Nov; 28(5):614-21. PubMed ID: 1979723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal caudate glucose metabolism in persons at risk for Huntington's disease.
    Young AB; Penney JB; Starosta-Rubinstein S; Markel D; Berent S; Rothley J; Betley A; Hichwa R
    Arch Neurol; 1987 Mar; 44(3):254-7. PubMed ID: 2950844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.
    Mazziotta JC; Phelps ME; Pahl JJ; Huang SC; Baxter LR; Riege WH; Hoffman JM; Kuhl DE; Lanto AB; Wapenski JA
    N Engl J Med; 1987 Feb; 316(7):357-62. PubMed ID: 2949152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington's disease.
    Baxter LR; Mazziotta JC; Pahl JJ; Grafton ST; St George-Hyslop P; Haines JL; Gusella JF; Szuba MP; Selin CE; Guze BH
    Arch Gen Psychiatry; 1992 Feb; 49(2):148-54. PubMed ID: 1532304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral metabolism of glucose in benign hereditary chorea.
    Suchowersky O; Hayden MR; Martin WR; Stoessl AJ; Hildebrand AM; Pate BD
    Mov Disord; 1986; 1(1):33-44. PubMed ID: 2973557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease.
    Hayden MR; Hewitt J; Stoessl AJ; Clark C; Ammann W; Martin WR
    Neurology; 1987 Sep; 37(9):1441-7. PubMed ID: 2957611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease.
    Harris GJ; Aylward EH; Peyser CE; Pearlson GD; Brandt J; Roberts-Twillie JV; Barta PE; Folstein SE
    Arch Neurol; 1996 Apr; 53(4):316-24. PubMed ID: 8929153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease.
    Kuhl DE; Metter EJ; Riege WH; Markham CH
    Ann Neurol; 1984; 15 Suppl():S119-25. PubMed ID: 6234856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography in the early diagnosis of Huntington's disease.
    Hayden MR; Martin WR; Stoessl AJ; Clark C; Hollenberg S; Adam MJ; Ammann W; Harrop R; Rogers J; Ruth T
    Neurology; 1986 Jul; 36(7):888-94. PubMed ID: 2940474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease.
    Aylward EH; Codori AM; Rosenblatt A; Sherr M; Brandt J; Stine OC; Barta PE; Pearlson GD; Ross CA
    Mov Disord; 2000 May; 15(3):552-60. PubMed ID: 10830423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan.
    Kuhl DE; Phelps ME; Markham CH; Metter EJ; Riege WH; Winter J
    Ann Neurol; 1982 Nov; 12(5):425-34. PubMed ID: 6217782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.
    Young AB; Penney JB; Starosta-Rubinstein S; Markel DS; Berent S; Giordani B; Ehrenkaufer R; Jewett D; Hichwa R
    Ann Neurol; 1986 Sep; 20(3):296-303. PubMed ID: 2945510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease.
    Kuhl DE; Markham CH; Metter EJ; Riege WH; Phelps ME; Mazziotta JC
    Res Publ Assoc Res Nerv Ment Dis; 1985; 63():199-209. PubMed ID: 3161165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene.
    Squitieri F; Esmaeilzadeh M; Ciarmiello A; Jankovic J
    Mov Disord; 2011 Apr; 26(5):925-7. PubMed ID: 21370274
    [No Abstract]   [Full Text] [Related]  

  • 17. Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data.
    D JF; Stout JC; Poudel G; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
    Br J Psychiatry; 2016 Jun; 208(6):571-8. PubMed ID: 26678864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [SPECT studies with 99mTc-HMPAO in Huntington's chorea patients].
    Botsch H; Oepen G; Deuschl G; Wolff G
    Rofo; 1987 Dec; 147(6):666-8. PubMed ID: 2827263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single photon emission computed tomography in Huntington's chorea.
    Leblhuber F; Hoell K; Reisecker F; Gebetsberger B; Puehringer W; Trenkler E; Deisenhammer E
    Psychiatry Res; 1989 Sep; 29(3):337-9. PubMed ID: 2532751
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease.
    Harris GJ; Codori AM; Lewis RF; Schmidt E; Bedi A; Brandt J
    Brain; 1999 Sep; 122 ( Pt 9)():1667-78. PubMed ID: 10468506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.